A startup can lose value long before anything officially goes wrong. No recall.No warning letter.No failed company announcement. Just growing doubt. An investor starts asking harder questions.The next round takes longer.The valuation discussion gets a little less confident.Then a little less generous. Why? Because valuation is not driven by promise alone.It is driven by how […]
Author: admin
Why Timelines Alone Are Misleading
The timeline looked brilliant. Prototype by June.Verification by September.FDA meeting by November.Submission next year. Clean. Sharp. Reassuring. Then reality showed up. One design change delayed testing.A risk issue changed the evidence plan.FDA feedback raised questions the team had not built for.Suddenly, the timeline that looked so certain started behaving like fiction. That is the problem […]
Why Most Regulatory Roadmaps Fail
Everything looks fine until FDA responds. The roadmap is on track. The milestones are moving. The team is hitting deadlines. Then the feedback arrives. FDA wants clarification on intended use. The evidence does not fully support the claims. A design choice creates new questions about risk. The submission path no longer looks as simple as […]
What Is a Regulatory Roadmap—Really?
A medical device company can look perfectly organized on paper and still be heading toward a regulatory mess. The timeline may look polished.Prototype by Q2. Verification by Q3. Submission next year. Investors feel reassured.The team feels productive.The board sees movement. Then one FDA meeting changes everything. The claims are too broad. The evidence plan is […]
Post-Investment Regulatory Risk Management
The deal closed.
Capital transferred. Board seats assigned. Milestones locked in. Everyone moved on.
Then, six months later, a quiet update arrived in the investor’s inbox:
“FDA has requested additional data.”
Timelines shifted. Burn rate climbed. The next round became a conversation nobody wanted to have. The investment wasn’t struggling because of the product — it was struggling because regulatory risk had been left unattended after the term sheet was signed.
This is more common than most investors realize.
Red Flags vs Acceptable Regulatory Risk
An investor once reviewed two startups in the same week.
Both had regulatory issues.
One deal moved forward.
The other was declined immediately.
Regulatory Documents That Actually Matter
An investor once reviewed a data room with over 300 regulatory documents.
Policies. SOPs. Test reports. Slide decks. Validation summaries.
Everything looked thorough.
Then a single question changed the entire deal:
“Where is the evidence that this pathway actually holds?”
Questions Investors Should Ask Founders About FDA Strategy
An investor once asked a founder a simple question:
“What happens if FDA disagrees with your pathway?”
The room went quiet.
Not because the answer was confidential.
Because there was no answer.
The deal didn’t collapse immediately.
But it never recovered.
How Should Investors Evaluate Regulatory Readiness?
An investor once said: “We didn’t pass on the company because the product was weak.We passed because we couldn’t tell if it would ever reach the market.” The founders had a strong device.The science made sense.The market was clear. But one question remained unanswered: “Are they actually ready to navigate FDA?” That uncertainty killed the […]